SCHEMBL2933382

SCHEMBL2933382

CC(C)CCNC(=O)[C@@H](NC(=O)c1cnc(-c2ccccc2)cn1)[C@@H](C)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.48
PSMB5 P28074 2/20 0.48
ELANE P08246 1/20 0.48
CTSG P08311 1/20 0.48
PSMB1 P20618 1/20 0.48
CMA1 P23946 1/20 0.48
PSMB8 P28062 1/20 0.48
PSMB9 P28065 1/20 0.48
PSMB10 P40306 1/20 0.48
PSMB2 P49721 1/20 0.48
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LAP3 P28838 2/20 0.43
ANPEP P15144 1/20 0.43
RNPEP Q9H4A4 1/20 0.43
DNPEP Q9ULA0 1/20 0.43
NAMPT P43490 2/20 0.42
SLC16A3 O15427 1/20 0.41
CNR1 P21554 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2934901 0.86 NPC1 (0.51) CYP3A4PSMB5ELANECTSGPSMB1
SCHEMBL2932158 0.84 PSMB5 (0.52) CYP3A4PSMB5ELANECTSGPSMB1
SCHEMBL2927879 0.84 ELANE (0.48) CYP3A4PSMB5ELANECTSGPSMB1
SCHEMBL608033 0.84 PSMB5 (0.68) CYP3A4PSMB5ELANECTSGPSMB1
SCHEMBL2933374 0.82 PSMB5 (0.48) CYP3A4PSMB5ELANECTSGPSMB1
SCHEMBL2931763 0.82 CTSA (0.48) CYP3A4PSMB5ELANECTSGPSMB1
SCHEMBL2934071 0.81 PSMB5 (0.73) CYP3A4PSMB5ELANECTSGPSMB1
SCHEMBL2926222 0.81 GRN (0.56) PSMB5NPC1RAB9ASMN1; SMN2GRN
SCHEMBL2925992 0.81 HDAC3 (0.42) CYP3A4PSMB5ELANECTSGPSMB1
SCHEMBL2934926 0.80 EPHX2 (0.51) CYP3A4PSMB5ELANECTSGPSMB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US claimed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP claimed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US claimed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US claimed
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US disclosed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189806-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 CYP3A4 4017/4885PSMB5 2/4885ELANE 1737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.